Abstract
Excretion of the major urinary bile alcohol 27-nor-5 beta-cholestane-3 alpha, 7 alpha, 12 alpha, 24,25- pentol , and of cholic, chenodeoxycholic, deoxycholic and lithocholic acid was measured in 24 h urine collections of 10 extensive and seven poor metabolizers of debrisoquine. There was no significant difference of the excretion of these cholesterol metabolites between the two groups, indicating that cholesterol hydroxylation to bile alcohols and bile acids is probably not controlled by the same genes responsible for the 'debrisoquine-type' hydroxylation polymorphism.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Almé B., Bremmelgaard A., Sjövall J., Thomassen P. Analysis of metabolic profiles of bile acids in urine using a lipophilic anion exchanger and computerized gas-liquid chromatorgaphy-mass spectrometry. J Lipid Res. 1977 May;18(3):339–362. [PubMed] [Google Scholar]
- Bertilsson L., Dengler H. J., Eichelbaum M., Schulz H. U. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol. 1980 Feb;17(2):153–155. doi: 10.1007/BF00562624. [DOI] [PubMed] [Google Scholar]
- Danielsson H., Gustafsson J. Biochemistry of bile acids in health and disease. Pathobiol Annu. 1981;11:259–298. [PubMed] [Google Scholar]
- Dick B., Küpfer A., Molnàr J., Braunschweig S., Preisig R. Hydroxylierungsdefekt für Medikamente (Typus Debrisoquin) in einer Stichprobe der Schweizer Bevölkerung. Schweiz Med Wochenschr. 1982 Jul 24;112(30):1061–1067. [PubMed] [Google Scholar]
- Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1982 Jan-Feb;7(1):1–22. doi: 10.2165/00003088-198207010-00001. [DOI] [PubMed] [Google Scholar]
- Hansson R., Wikvall K. Hydroxylations in biosynthesis and metabolism of bile acids. Catalytic properties of different forms of cytochrome P-450. J Biol Chem. 1980 Feb 25;255(4):1643–1649. [PubMed] [Google Scholar]
- Idle J. R., Oates N. S., Shah R. R., Smith R. L. Protecting poor metabolizers, a group at high risk of adverse drug reactions. Lancet. 1983 Jun 18;1(8338):1388–1388. doi: 10.1016/s0140-6736(83)92172-4. [DOI] [PubMed] [Google Scholar]
- Karlaganis G., Almé B., Karlaganis V., Sjövall J. Bile alcohol glucuronides in urine. Identification of 27-nor-5 beta-cholestane 3 alpha, 7 alpha, 12 alpha, 24 xi, 25 xi-pentol in man. J Steroid Biochem. 1981 Apr;14(4):341–345. doi: 10.1016/0022-4731(81)90152-7. [DOI] [PubMed] [Google Scholar]
- Karlaganis G., Nemeth A., Hammarskjöld B., Strandvik B., Sjövall J. Urinary excretion of bile alcohols in normal children and patients with alpha 1-antitrypsin deficiency during development of liver disease. Eur J Clin Invest. 1982 Oct;12(5):399–405. doi: 10.1111/j.1365-2362.1982.tb00687.x. [DOI] [PubMed] [Google Scholar]
- Lennard M. S., Silas J. H., Smith A. J., Tucker G. T. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr. 1977 Mar 11;133(1):161–166. doi: 10.1016/s0021-9673(00)89216-x. [DOI] [PubMed] [Google Scholar]
- Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
- Park B. K., Eichelbaum M., Ohnhaus E. E. 6 beta-hydroxycortisol excretion in relation to polymorphic N-oxidation of sparteine. Br J Clin Pharmacol. 1982 May;13(5):737–740. doi: 10.1111/j.1365-2125.1982.tb01448.x. [DOI] [PMC free article] [PubMed] [Google Scholar]